Can't Say No: Pharma's Addiction to Shareholder Payouts
Executive Summary
Having created a shareholder addiction to cash payments, companies are now going to have to make the unpleasant choice between pleasing investors in the short term and building their businesses over the next decade. IN VIVO examines pipeline confidence, patent expirations, and cash flow woes to make some forecasts about the industry's financial health, as well as looking inside the strategies that Big Pharma is currently pursuing.
You may also be interested in...
Best of the Blog February 2010
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In February, Windhover's editorial staff posted 26 articles to the site, covering biopharma R&D, business development, regulatory, and commercial news.
Best of the Blog February 2010
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In February, Windhover's editorial staff posted 26 articles to the site, covering biopharma R&D, business development, regulatory, and commercial news.
Pharma Share Buybacks Could Draw Policymakers’ Scrutiny, Professor Warns
In current economic climate, trade-offs between buybacks and R&D investment could get a closer look, University of Massachusetts prof says at economic conference.